What is the standard of care for early stage Liver Cancer according to NCCN guidelines

Standard of Care for Early-Stage Liver Cancer (HCC)

Based on the NCCN Guidelines Version 2.2025 for Hepatocellular Carcinoma, here's what constitutes standard care for early-stage disease:

How Early-Stage HCC Is Identified

According to NCCN Guidelines, early-stage HCC is typically identified through:

• Screening and surveillance imaging using ultrasound (US) every 6 months in high-risk patients (those with cirrhosis or chronic hepatitis B)
• Contrast-enhanced CT or MRI to confirm diagnosis and stage the tumor burden in the liver
• LI-RADS criteria (Liver Imaging Reporting and Data System) to standardize how doctors interpret imaging findings

Treatment Options for Early-Stage, Resectable Disease

For patients with early-stage HCC who are candidates for surgery, the NCCN Guidelines recommend considering:

Surgery (Partial Hepatectomy)

This is a potentially curative approach for well-selected patients with:

• A solitary tumor (any size) with no evidence of vascular invasion
• Preserved liver function
• Good performance status (ability to tolerate surgery)

Key outcomes: Large studies show 5-year survival rates of >50% for patients undergoing liver resection, with some studies reporting approximately 70% five-year survival for selected patients with preserved liver function and early-stage disease.

Important consideration: Recurrence rates at 5 years can exceed 70%, so close follow-up surveillance is essential.

Locoregional Therapy (for liver-confined, unresectable disease)

If surgery isn't an option, NCCN Guidelines recommend considering:

• Ablation (destroying the tumor with heat or cold)
• Arterially directed therapies (chemoembolization - delivering chemotherapy directly to the tumor)
• Radiation therapy

Critical Assessment Before Treatment

Before any treatment, your multidisciplinary team evaluates:

• Liver function using the Child-Turcotte-Pugh (CTP) score
• Portal hypertension (increased pressure in the vein bringing blood to the liver)
• Patient performance status (overall health and ability to tolerate treatment)
• Tumor characteristics (size, location, number of tumors)

Post-Treatment Surveillance

According to NCCN Guidelines, after successful treatment:

• Imaging (CT or MRI) every 3-6 months for 2 years, then every 6 months
• AFP blood test (alpha-fetoprotein, a tumor marker) every 3-6 months for 2 years, then every 6 months
• Surveillance should continue for at least 5 years

Why Multidisciplinary Care Matters

The NCCN Guidelines emphasize that all patients with HCC should be evaluated by an experienced multidisciplinary team including:

• Hepatologists (liver specialists)
• Diagnostic and interventional radiologists
• Surgeons
• Medical oncologists
• Radiation oncologists
• Pathologists with HCC expertise

This is critical because HCC management is complicated by underlying liver disease, and different causes of liver disease can affect treatment response and outcomes.

Key Questions to Ask Your Healthcare Team

1. Does my tumor meet criteria for surgical resection, and what is my liver function status?
2. What is my Child-Turcotte-Pugh score, and do I have signs of portal hypertension?
3. If surgery isn't an option, which locoregional therapy would be most appropriate for my tumor location and size?
4. What is the expected 5-year recurrence rate for my specific situation?
5. What will my surveillance schedule look like after treatment?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.